Pols One, 2021

This double-blind, randomized, placebo-controlled trial found that treatment with cannabis led to a significant reduction in the Lichtiger Disease Activity Index, and improvement in major IBD-related clinical symptoms including abdominal pain and number of bowel movements per day.

Key Results:

• 90% of patients reported decreased stomach pain after using medical cannabis, after failing to see improvement using conventional medicines
  62% of respondents saw an improvement in bowel activity, 54% saw a decrease in disease severity
• Short term treatment with THC rich cannabis induced clinical remission and improved quality of life, general health, appetite, libido, and concentration.
• A marked improvement in clinical disease severity between the cannabis group and the placebo group was noted, with some patients entering remission.
  

Study Population: 32 patients with Ulcerative Colitis

Strain Used: Erez